Literature DB >> 18583172

Chronic intraventricular administration of 1-methyl-4-phenylpyridinium as a progressive model of Parkinson's disease.

Patricia K Sonsalla1, Gail D Zeevalk, Dwight C German.   

Abstract

Animal models of Parkinson's disease (PD) that more closely exhibit the chronic neuropathology seen in the human condition are needed in order to reveal processes involved with progressive neurodegeneration and for testing potential interventions for retarding dopamine (DA) neuronal loss. Here we describe the recently developed chronic rat model of PD in which 1-methyl-4-phenylpyridinium ion (MPP(+)) is infused chronically into the lateral cerebral ventricle. We review features of this model that include loss of nigral DA neurons, swollen and abnormal mitochondria, striatal inclusion-like bodies and microgliosis. Advantages as well as limitations of the model are addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583172      PMCID: PMC2577902          DOI: 10.1016/j.parkreldis.2008.04.008

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

1.  Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+).

Authors:  U Yazdani; D C German; C-L Liang; L Manzino; P K Sonsalla; G D Zeevalk
Journal:  Exp Neurol       Date:  2006-03-20       Impact factor: 5.330

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

4.  Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease.

Authors:  G D Zeevalk; L Manzino; P K Sonsalla; L P Bernard
Journal:  Exp Neurol       Date:  2006-10-17       Impact factor: 5.330

5.  Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.

Authors:  E Petroske; G E Meredith; S Callen; S Totterdell; Y S Lau
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines.

Authors:  P A Trimmer; R H Swerdlow; J K Parks; P Keeney; J P Bennett; S W Miller; R E Davis; W D Parker
Journal:  Exp Neurol       Date:  2000-03       Impact factor: 5.330

7.  Ultrastructural changes of the substantia nigra, ventral tegmental area and striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

Authors:  K Mizukawa; Y H Sora; N Ogawa
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-03

8.  Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey.

Authors:  J Tanaka; H Nakamura; S Honda; K Takada; S Kato
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

9.  Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP.

Authors:  David D Song; Clifford W Shults; Abbyann Sisk; Edward Rockenstein; Eliezer Masliah
Journal:  Exp Neurol       Date:  2004-04       Impact factor: 5.330

  9 in total
  7 in total

1.  P-Glycoprotein Transport of Neurotoxic Pesticides.

Authors:  Sarah E Lacher; Kasse Skagen; Joachim Veit; Rachel Dalton; Erica L Woodahl
Journal:  J Pharmacol Exp Ther       Date:  2015-08-13       Impact factor: 4.030

2.  2, 2'- and 4, 4'-Cyanines are transporter-independent in vitro dopaminergic toxins with the specificity and mechanism of toxicity similar to MPP⁺.

Authors:  Chamila C Kadigamuwa; Viet Q Le; Kandatege Wimalasena
Journal:  J Neurochem       Date:  2015-08-12       Impact factor: 5.372

3.  Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Authors:  Nicoletta Schintu; Lucia Frau; Marcello Ibba; Arianna Garau; Ezio Carboni; Anna R Carta
Journal:  Neurotox Res       Date:  2009-05-27       Impact factor: 3.911

4.  Characteristics of the mitochondrial and cellular uptake of MPP+, as probed by the fluorescent mimic, 4'I-MPP.

Authors:  Mapa S T Mapa; Viet Q Le; Kandatege Wimalasena
Journal:  PLoS One       Date:  2018-08-23       Impact factor: 3.240

5.  Altered expression of miR-29a-3p and miR-34a-5p by specific inhibition of GSK3β in the MPP+ treated SH-SY5Y Parkinson's model.

Authors:  Morteza Ahmadzadeh-Darinsoo; Mojtaba Ahmadzadeh-Darinsoo; Shahsanam Abbasi; Ehsan Arefian; Claude Bernard; Azita Parvaneh Tafreshi
Journal:  Noncoding RNA Res       Date:  2022-01-07

6.  Involvement of the ERK pathway in the protective effects of glycyrrhizic acid against the MPP+-induced apoptosis of dopaminergic neuronal cells.

Authors:  Lesheng Teng; Chunjia Kou; Chengyu Lu; Jiaming Xu; Jing Xie; Jiahui Lu; Yan Liu; Zhenzuo Wang; Di Wang
Journal:  Int J Mol Med       Date:  2014-07-02       Impact factor: 4.101

7.  Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra.

Authors:  Jun-Fang Chen; Man Wang; Ying-Han Zhuang; Thomas Behnisch
Journal:  Neural Regen Res       Date:  2018-04       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.